Matthew Jarvis serves as a Principal Scientist at Biosplice Therapeutics, where he leverages his extensive expertise in bioinformatics and molecular biology to drive innovative research in clinical cancer genomics and therapeutic development. At Biosplice, a pioneer in the field of alternative pre-mRNA splicing, Matthew plays...
Matthew Jarvis serves as a Principal Scientist at Biosplice Therapeutics, where he leverages his extensive expertise in bioinformatics and molecular biology to drive innovative research in clinical cancer genomics and therapeutic development. At Biosplice, a pioneer in the field of alternative pre-mRNA splicing, Matthew plays a crucial role in advancing the understanding of how splicing mechanisms can be harnessed to create first-in-class small-molecule therapeutics. His work is particularly focused on elucidating the novel biology linking CLK/DYRK kinases to the therapeutic regulation of alternative splicing, a groundbreaking area that holds significant promise for cancer treatment.
Matthew's current projects involve the integration of advanced techniques such as next-generation sequencing and RNA isolation to dissect the complexities of splicing events in cancer cells. By employing his skills in nucleic acid extraction and molecular cloning, he is able to develop robust models that reveal the impact of splicing alterations on tumorigenesis and therapeutic resistance. His proficiency in cell culture and ELISA further enhances his ability to validate findings in vitro, ensuring that the therapeutic candidates developed at Biosplice are grounded in solid scientific evidence.
In addition to his technical skills, Matthew's critical thinking and independent research approach enable him to navigate the challenges of translating basic science into clinical applications. His contributions not only advance the mission of Biosplice Therapeutics but also position him as a thought leader in the rapidly evolving landscape of cancer therapeutics, where the modulation of splicing presents a frontier for innovative treatment strategies.
